Cardiovascular comorbidities and obstructive sleep apnea by Cintra, Fátima Dumas et al.
Arquivos Brasileiros de Cardiologia - Volume 86, Nº 6, June 2006
UpdateUpda e
Cardiovascular Comorbidities and Obstructive Sleep 
Apnea
Fátima Dumas Cintra, Dalva Poyares, Christian Guilleminault, Antonio Carlos Carvalho, 
Sergio Tufik, Angelo A. V. de Paola
Universidade Federal de São Paulo e Stanford University - São Paulo, SP, Brazil - Stanford, CA , USA
Mailing Address: Fátima Dumas Cintra • Av. Marcos Penteado de Ulhoa Rodrigues, 1001 - 06543-330 – Santana de Parnaíba, SP - Brazil
E-mail: fatimacintra@interair.com.br  Received on 12/08/05 • Accepted on 12/28/05
Obstructive sleep apnea-hypopnea syndrome (OSAHS) 
is a prevalent condition in the general population. It is 
associated with increased cardiovascular risk and often 
goes unrecognized. Its diagnose requires a high degree of 
clinical suspicion, particularly on the part of cardiologists, 
and it may be confi rmed by polysomnography. Continuous 
positive airway pressure (CPAP) therapy is highly effective, 
since it improves sleep breathing pattern, promotes 
restful sleep and thus enhances the quality of life of 
these patients, in addition to attenuating or reversing 
many cardiovascular complications related to OSAHS. 
This paper addresses the pathophysiology and clinical 
features of cardiovascular comorbidities associated with 
the syndrome.
INTRODUCTION
Cardiovascular disease is one of the primary causes 
of mortality worldwide1. In the city of São Paulo, 
cardiovascular diseases associated with atherosclerosis 
are the leading cause of death, similar to developed 
countries2,3. A number of studies4-6 confi rm the role of 
cigarette smoking, high LDL-cholesterol levels, low HDL-
cholesterol levels, diabetes mellitus, systemic arterial 
hypertension, family history, obesity, physical inactivity, 
central obesity, metabolic syndrome, and alcohol 
consumption in the genesis of atherosclerosis and its 
clinical complications.
In addition to these factors, recent evidence shows 
increased cardiovascular mortality in patients with 
obstructive sleep apnea-hypopnea syndrome (OSAHS)7. 
The role of this syndrome as a cardiovascular risk factor 
deserves the careful attention of the cardiologist, because 
this condition is often undiagnosed8. 
OSAHS is a disorder characterized by recurrent 
complete or partial upper airway obstruction during 
sleep, resulting in apneic episodes, oxyhemoglobin 
desaturation, frequent arousals (fi gures 1 and 2) and 
consequent daytime sleepiness. This syndrome is far 
more common in men. Its incidence in middle-aged 
men and women in the literature ranges from 1% and 
5% and 1.2% and 2.5%, respectively9-13, and may 
increase with age14. It is often associated with other 
cardiovascular diseases; moreover, it is estimated that 
40% of the patients with systemic hypertension have 
OSAHS, undiagnosed and untreated15,16. 
Chart 1 shows some important defi nitions for inter-
preting and diagnosing this condition.
PATHOPHYSIOLOGY
Increased upper airway collapse during sleep is 
associated with increased respiratory effort and change 
in nasal and oral airfl ow, which may trigger hypoxemia 
and hypercapnia20. This process results in arousal with 
resumption of breathing. Abnormal respiratory events and 
arousals may alternate many times during the night21. 
During each episode of obstructive apnea/hypopnea, 
the inspiratory effort against an occluded airway is 
accompanied by negative pressure in the pleural space. As 
apnea persists, hypoxemia and hypercapnia become more 
marked, leading to pulmonary vasoconstriction and the 
development of transient pulmonary hypertension. There 
is however, a stimulation of the sympathetic nervous 
system, causing systemic vasoconstriction and arterial 
hypertension; in some cases, systolic blood pressure may 
reach signifi cantly high nocturnal levels, even in subjects 
with normal daytime blood pressure 
Additionally, the hypoxia and subsequent reoxygenation 
phenomenon, repeated many times during the night, 
causes changes in reperfusion, with free radical 
production23, and oxidative stress is now considered a 
major contributor to the cardiovascular consequences 
observed in this group of patients24. Association of 
OSAHS with obesity25, predominance in male and 
postmenopausal women, as well as the systemic effects 
triggered with its onset, strongly suggest that OSAHS is 
a systemic disease, rather than a local abnormality26,27. 
Other important evidence favoring the systemic disease 
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Fig. 1 – Example of a compressed overnight polysomnographic graph in a patient with marked obstructive sleep apnea. A) hypnogram; B) apneic and 
hypopneic events; C) frequent events with marked drops in oxyhemoglobin saturation; D) microarousals (sleep fragmentation); E) loud and frequent 
snoring
hypothesis for OSAHS is its correlation with higher 
infl ammatory cytokine levels and insulin resistance. 
Inflammatory cytokines, tumor necrosis factor-α 
(TNF- α), and interleukin-6 (IL-6) are involved in the 
physiological regulation of sleep28 and are abnormally 
elevated in apneic patients, when compared to normal 
and obese subjects29,30. However, the correlation between 
OSAHS and insulin resistance seems to be independent 
of obesity31.
CARDIOVASCULAR CONSEQUENCES
The main cardiovascular consequences are changes in 
autonomic nervous system activity, arterial hypertension, 
cardiac arrhythmias, coronary artery disease, stroke, and 
congestive heart failure.
Changes in autonomic nervous system 
activity
Heart rate and blood pressure changes observed 
in obstructive sleep apnea are likely to be secondary 
to autonomic nervous system activation during every 
apneic event32. This was demonstrated even in patients 
with mild OSAHS33,34. During these events, a progressive 
increase in sympathetic activity occurs, reaching its peak 
at apnea termination, followed by a marked decrease 
during recovery35,36. 
However, the mechanisms by which OSAHS causes 
persistent sympathetic activation, that is, even during 
wakefulness, are not entirely clear. Some evidence 
emphasizes the role of hypoxia in this phenomenon: 
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Fig. 2 – Example of a compressed overnight polysomnographic graph in a patient with marked obstructive sleep apnea followed by the introduction of 
nasal CPAP. A) observe the hypnogram, number of abnormal breathing events and intense oxyhemoglobin desaturation. B) after nasal CPAP introduction, 
observe the normalization of hypnogram with REM sleep rebound recording, abnormal breathing events, and oxyhemoglobin desaturation
A B
Chart 1 – Term Defi nition17-19
Term Defi nition
Polysomnography
Polygraphic sleep recording, including electroencephalogram (EEG), electroocculogram (EOG), 
electromyogram (EMG), electrocardiogram (ECG), and respiratory parameters.
NREM sleep Characterized by electroencephalographic slow waves associated with specifi c graphic elements.
REM sleep Characterized by EEG desynchronization, rapid eye movements, muscle atonia, and dreams.
Arousals Transient awakening lasting more than three seconds.
Apnea Reduction of > 80% in oronasal airfl ow during more than ten seconds.
Hypopnea
Reduction of > 20% in oronasal airfl ow during more than ten seconds, usually accompanied by either a 
decrease in oxyhemoglobin saturation or an arousal
Apnea-hypopnea index (AHI) Frequency of apneic or hypopneic episodes per hour of sleep; it is a measure of sleep apnea severity.
Oxygen desaturation Decrease of > 3% in oxyhemoglobin saturation, often caused by apnea or hypopnea.
Obstructive sleep apnea-hypopnea 
syndrome
AHI > fi ve per hour of sleep accompanied by symptoms such as snoring, restless sleep, nocturnal 
dyspnea, morning headaches, excessive daytime sleepiness, and arterial hypertension.
urinary norepinephrine concentrations are inversely 
proportional to nadir nocturnal oxyhemoglobin saturation. 
Furthermore, the ventilatory changes that determine 
hypoxia and hypercapnia cause an increase in muscle 
sympathetic nerve activity, which may persist for up 
to twenty minutes following stimulus withdrawal37. 
The carotid sinus seems to play a role in the process 
between exposure to intermittent nocturnal hypoxia and 
development of sustained elevation in autonomic activation 
levels, because barorefl ex regulation and sensitivity are 
reduced in patients with OSAHS, compared to controls38. 
Current evidence suggests that the intermittent nocturnal 
hypoxic stimulus of peripheral chemoreceptors increases 
the sympathetic tone in these patients even during 
wakefulness and optimal oxygen supply39,40. 
Moreover, autonomic nervous system studies employing 
heart rate variability demonstrate that the high-frequency 
component (parasympathetic tone) of heart rate variability 
of OSAHS patients declines and the low-frequency 
component (sympathetic tone) increases. This abnormal 
pattern seems to refl ect sympathetic predominance in the 
autonomic modulation of OSAHS41.
CARDIOVASCULAR COMORBIDITIES AND OBSTRUCTIVE SLEEP APNEA
Arquivos Brasileiros de Cardiologia - Volume 86, Nº 6, June 2006
Hypertension
OSAHS is an independent risk factor for systemic 
arterial hypertension (SAH)42-47. SAH prevalence in 
OSAHS patients ranges from 40% to 90%, and the 
opposite, OSAHS prevalence in SAH patients, ranges 
from 22% to 62%43. Recent studies corroborate this high 
prevalence between both conditions48 and show that, in 
four years, subjects with apnea/hypopnea index (AHI) 
greater than fi fteen per hour of sleep have a fi ve-fold risk 
(45% likelihood) of developing SAH43. A study with 44 
patients with drug-resistant hypertension showed that 
83% had OSAHS49.OSAHS patients show great blood 
pressure (BP) variability during the night, and they may 
not experience the nocturnal dip observed in normal 
patients, resulting in higher mean night-time BP values, 
even when daytime BP is normal. This BP behavior may 
be due to negative intrathoracic pressure with reduced 
cardiac output and differential activation of baroreceptors, 
hypoxia, hypercapnia, breathing-related arousal and 
increased sympathetic activity50. 
Continuous positive airway pressure (CPAP) has 
proved to be effective in the treatment of patients with 
OSAHS and SAH51,52. In a series of eleven patients with 
refractory SAH, CPAP reduced nocturnal blood pressure53. 
Furthermore, in twelve patients with severe OSAHS, the 
use of CPAP decreased plasma norepinephrine and urinary 
catecholamine metabolites54.
Thus far, therefore, OSAHS should be considered in 
the differential diagnosis of refractory systemic arterial 
hypertension, and the use of CPAP may help in reducing 
both daytime and night-time blood pressure55,56. 
Cardiac arrhythmias
Some authors have already studied the relationship 
between OSAHS and cardiac arrhythmias57,58; however, 
there is no consensus in the medical literature concerning 
results57,58 and prevalence of tachyarrhythmia and 
bradyarrhythmia. This may be partly explained by the 
unknown incidence of OSAHS in the general healthy 
population and by the high incidence of hypertension and 
cardiovascular diseases in OSAHS patients. However, it 
is known that the use of CPAP in OSAHS patients may 
reduce cardiac arrhythmias, just as artifi cial cardiac 
stimulation may attenuate breathing disorders59,60. Figure 
3 shows an example of sinus pause associated with apneic 
event in an OSAHS patient. 
Atrial fi brillation (AF) deserves underscoring, because 
it has been studied in the largest number of clinical 
trials related to sleep-disordered breathing61-66. Its 
prevalence seems to increase in patients with OSAHS 
and congestive heart failure (CHF) or recent myocardial 
revascularization61,62. As already stated, OSAHS causes 
intermittent hypoxemia, sympathetic activation, and 
abrupt changes in blood pressure, which may be related 
to the development and recurrence of AF. In a prospective 
study62 of patients referred for electrical cardioversion 
of atrial fi brillation/atrial fl utter, 82% of the untreated 
or inadequately treated OSAHS patients experienced 
recurrent AF, compared to 42% of the treated patients. 
Moreover, in the untreated group, recurrence was even 
higher among those who showed greater drop in oxygen 
saturation during the apneic event. These data suggest 
that appropriate treatment with CPAP may reduce AF 
recurrence in OSAHS patients. 
Ventricular ectopies were reported in up to 66% of 
OSAHS patients. However, in a prospective study of 147 
patients who underwent simultaneous polysomnography 
and Holter monitoring, no increase in ventricular 
arrhythmias was found67. In view of discrepant reports 
in the medical literature, it is diffi cult to establish a 
direct relationship between the syndrome and ventricular 
arrhythmias. Yet, analyzing the relationship between 
ventricular ectopies and oxyhemoglobin desaturation 
in patients with OSAHS68, a marked increase is found 
in ventricular ectopy frequency when oxygen saturation 
drops below 60%, and the relationship between apneic 
events and ventricular arrhythmias seems to exist solely in 
patients with important desaturation during the night. 
Patients with this syndrome experience ventricular 
arrhythmias mainly during sleep, unlike patients with 
normal sleep68, and ventricular tachycardia is more 
common in OSAHS patients (0-15%) than in the general 
population (0-4%)69. Bradyarrhythmias are strongly 
associated with OSAHS. Guilleminault et al.70 have 
found sinus pause (> 2.5 seconds), second-degree 
atrioventricular block, and sinus bradycardia in 11%, 
8%, and 7% of the patients, respectively. Koehler et 
al.71 analyzed factors involved in heart blocks in patients 
with OSAHS and concluded that most cases occur during 
REM sleep and periods with oxygen desaturation of at 
least 4%. 
Despite confl icting reports in the literature, oxygen 
saturation drop during apneic episodes seems to be an 
important factor triggering cardiac arrhythmias in patients 
with sleep apnea-hypopnea syndrome, and its frequency 
is associated with hypoxia severity.
Coronary artery disease
Despite the growing incidence of OSAHS and the 
concomitant increase in cardiovascular mortality9, most 
studies face important limitations, because many risk 
factors, such as obesity, masculine gender and age, 
among others, are the same as those for hypertension 
and coronary artery disease (CAD). Therefore, it seems 
diffi cult to pinpoint the risk for CAD attributed to OSAHS; 
however, convergent observations suggest that OSAHS is 
an important factor associated with CAD. 
In OSAHS, the increase in peripheral sympathetic 
nerve activity during sleep to twice the normal values 
persists during wakefulness72 and may contribute to 
acute coronary events in the early morning hours. In 
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addition to autonomic nervous system involvement, 
both the infl ammation and endothelial injury observed 
in OSAHS are likely to participate in the mechanisms 
involved in CAD73. 
In a well-conducted study evaluating the impact of 
OSAHS therapy on long-term cardiovascular outcomes 
(86.5 ± 39 months) in CAD patients, those appropriately 
treated experienced a signifi cant reduction in cardiovascular 
event risk, defined as cardiovascular death, acute 
coronary syndrome, admission for heart failure, or need 
of myocardial revascularization74. 
Nocturnal ST-segment changes consistent with 
myocardial ischemia are common in patients with 
OSAHS and CAD. Mooe et al75 evaluated the occurrence 
of nocturnal myocardial ischemia and its relationship to 
sleep-related breathing disorders. ST-segment depressions 
occurred in 31% of the patients studied. Temporal 
association between electrocardiographic fi ndings and 
apneic events was found in 19% of the cases, more 
frequently in men (p < 0.01) and in more severely 
disordered breathing. 
Stroke
Among stroke patients, sleep-disordered breathing 
incidence, the obstructive form predominantly, may 
exceed 50%76. It remains quite unclear, however, whether 
these events detected after stroke are a consequence of 
the cerebrovascular event or a preexistent condition. As 
with coronary artery disease, OSAHS and stroke also 
share many risk factors, and it is equally diffi cult to prove 
a cause-effect relationship. 
Dziewas et al77 analyzed the frequency of sleep-
disordered breathing in groups of patients with fi rst and 
recurrent ischemic stroke. Patients with recurrent stroke 
showed higher mean apnea-hypopnea index (AHI) when 
compared to patients with fi rst-ever stroke (26.6/h vs. 
15.1/h, p < 0.05) and most commonly had OSAHS. In 
the multivariate analysis adjusted for clinical variables and 
risk factors, sleep apnea was considered an independent 
risk factor for stroke recurrence, and the authors advocate 
the use of polysomnography in this group of patients for 
risk stratifi cation.
OSAHS most probably contributes to recurrent stroke 
through several mechanisms, such as systemic arterial 
hypertension, increased platelet aggregation, blood 
hypercoagulability, and endothelial dysfunction, among 
others. Moreover, blood fl ow to the brain declines during 
apnea, due to reduction in cardiac output, which may 
predispose risk subjects to stroke, such as those with 
atheromatous lesions in carotid and vertebral circulations. 
This may be signifi cantly more important during REM 
sleep, when brain oxygen demand is higher. 
In addition, apnea may impair cognitive function in 
patients with previous history of stroke, since it causes 
excessive daytime sleepiness and poor concentration 
Fig. 3 – Example of a thirty-second epoch graphic containing an obstructive sleep apnea event with sinus pause followed by increment in heart rate
REM sleep
Obstructive sleep apnea
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and memory78. Finally, randomized clinical trials 
examining apnea therapy and neurological outcomes 
are still lacking.
Congestive heart failure
Several studies also showed an important association 
between congestive heart failure (CHF) and OSAHS. In 
the Javaheri et al79 study, 81 men with CHF underwent 
polysomnography, and 11% were found to have 
obstructive sleep apnea syndrome. In the Sleep Heart 
Health study80, apneic patients with an AHI > 11 per 
hour showed a 2.38 risk of developing CHF, regardless 
of other established risk factors, exceeding those found 
for other cardiovascular complications associated with 
OSAHS, such as hypertension, CAD, and stroke. 
It is also believed that CHF contributes to the 
development of OSAHS for two reasons, namely, 
decreased upper airway muscle tone during the resting 
phase of the periodic breathing typical of CHF and fl uid 
accumulation in the soft tissues of the cervical region, 
contributing to the tendency of upper airway collapse.
Echocardiographic studies showed both systolic81 
and diastolic82 dysfunction with increasing AHI. Possible 
mechanisms include hypoxia effects (determining 
ischemia and impaired contractility), myocyte injury 
(due to higher levels of circulating catecholamines), and 
intrathoracic pressure swings that accompany apneic 
episodes (changing relaxation and left ventricular end-
systolic and end-diastolic volumes).
Finally, the diagnosis of sleep-disordered breathing 
in CHF patients may provide valuable prognostic 
information and a potential therapeutic option for this 
group of patients83. 
Inflammatory, endothelial, and 
thrombotic changes in osahs
Decline or absence of physiological mechanisms 
involved in vascular relaxation was demonstrated 
in response to endothelium-dependent substances 
(increased vasoconstrictor, endothelin, and reduced nitric 
acid and prostacyclin availability)84,85. Another evidence 
of endothelial damage was documented by enhanced 
expression of adhesion molecules, leading to increased 
adherence of monocytes to endothelial cells86. OSAHS 
may also trigger recurrent oxidative stress87, probably 
owing to greater production of oxygen-reactive species 
by monocytes and granulocytes. These fi ndings reinforce 
previous results regarding increased production of 
superoxide radicals from polymorphonuclear neutrophils 
in patients with OSAHS88 and low levels of nitric oxide89. 
Plasma homocystein levels were also reported to be 
elevated in this syndrome90, as a result of endothelial 
dysfunction combined with excessive production of free 
radicals. Serium haptoglobin and amyloid A protein were 
also reported to be higher91,92. 
The relationship between infl ammatory process and 
cardiovascular diseases has been repeatedly postulated93. 
OSAHS patients are chronically exposed to recurrent 
hypoxia and sleep fragmentation, showing increased 
C-reactive protein and interleukin-6 levels, when 
compared to controls94. It is also likely that C-reactive 
protein levels in these patients are higher because of 
associated obesity95. All these endothelial, blood clotting, 
and infl ammatory changes may contribute somewhat to 
higher cardiovascular risk and atherogenesis in OSAHS 
patients. Finally, CPAP therapy may improve these 
changes; however, discontinuation of therapy leads to 
the reappearance of abnormalities96-103. 
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